In response to the FDA approval of brexucabtagene autoleucel for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), the panel requested the consideration of brexucabtagene autoleucel for this indication.

External request
Submission request from Kite (06/24/20) to consider the addition of brexucabtagene autoleucel as a second line therapy for relapsed or refractory MCL.

Based on the data in the noted reference and the recent FDA approval, the panel consensus was to include brexucabtagene autoleucel as an option only after chemoimmunotherapy and BTK inhibitor for the following indications:

- Short response duration to prior chemoimmunotherapy (< expected median PFS) a category 2A, useful in certain circumstances recommendation
- Extended response duration to prior chemoimmunotherapy (> expected median PFS) a category 2A, useful in certain circumstances recommendation